Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-03-19
2011-11-29
Anderson, Rebecca (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S326000, C514S361000, C514S364000, C514S414000, C514S422000, C546S209000, C544S134000, C548S125000, C548S465000, C548S518000
Reexamination Certificate
active
08067414
ABSTRACT:
The invention provides compositions and kits comprising at least one nitric oxide enhancing prostaglandin compound or a pharmaceutically acceptable salt thereof, and, optionally, at least one nitric oxide enhancing compound and/or at least one therapeutic agent. The invention also provides methods for (a) treating ophthalmic disorders; (b) treating cerebrovascular disorders; (c) treating cardiovascular disorders; (d) treating benign prostatic hyperplasia (BPH); (e) treating peptic ulcers; (e) treating sexual dysfunctions and (f) inducing abortions. The nitric oxide enhancing prostaglandin compounds comprise at least one heterocyclic nitric oxide donor group and/or at least one nitroxide group.
REFERENCES:
patent: 4868179 (1989-09-01), Cohn
patent: 5284872 (1994-02-01), Sandrock et al.
patent: 5344991 (1994-09-01), Reitz et al.
patent: 5380738 (1995-01-01), Norman et al.
patent: 5380758 (1995-01-01), Stamler et al.
patent: 5393790 (1995-02-01), Reitz et al.
patent: 5409944 (1995-04-01), Black et al.
patent: 5428061 (1995-06-01), Sandrock et al.
patent: 5434178 (1995-07-01), Talley et al.
patent: 5436265 (1995-07-01), Black et al.
patent: 5466823 (1995-11-01), Talley et al.
patent: 5474995 (1995-12-01), Ducharme et al.
patent: 5510368 (1996-04-01), Lau et al.
patent: 5536752 (1996-07-01), Ducharme et al.
patent: 5550142 (1996-08-01), Ducharme et al.
patent: 5552422 (1996-09-01), Gauthier et al.
patent: 5604253 (1997-02-01), Lau et al.
patent: 5604260 (1997-02-01), Guay et al.
patent: 5639780 (1997-06-01), Lau et al.
patent: 5650447 (1997-07-01), Keefer et al.
patent: 5661129 (1997-08-01), Feelisch et al.
patent: 5703073 (1997-12-01), Garvey et al.
patent: 5703758 (1997-12-01), Snyder et al.
patent: 5807847 (1998-09-01), Thatcher et al.
patent: 5883122 (1999-03-01), Thatcher et al.
patent: 5910316 (1999-06-01), Keefer et al.
patent: 5932598 (1999-08-01), Talley et al.
patent: 6133272 (2000-10-01), Garvey et al.
patent: 6172068 (2001-01-01), Garvey et al.
patent: 6177428 (2001-01-01), Garvey et al.
patent: 6197778 (2001-03-01), Garvey et al.
patent: 6197782 (2001-03-01), Garvey et al.
patent: 6211179 (2001-04-01), Garvey et al.
patent: 6221881 (2001-04-01), Garvey et al.
patent: 6232321 (2001-05-01), Garvey et al.
patent: 6232336 (2001-05-01), Hrabie et al.
patent: RE37234 (2001-06-01), Garvey et al.
patent: 6316457 (2001-11-01), Garvey et al.
patent: 6331542 (2001-12-01), Carr et al.
patent: 6633272 (2003-10-01), Kumagawa et al.
patent: 7273946 (2007-09-01), Ongini et al.
patent: 2004/0171681 (2004-09-01), Orihashi et al.
patent: 2005/0153946 (2005-07-01), Hirsh et al.
patent: 2005/0272743 (2005-12-01), Ongini et al.
patent: 574726 (1993-12-01), None
patent: 683159 (1995-11-01), None
patent: WO-9309806 (1993-05-01), None
patent: WO-9401422 (1994-01-01), None
patent: WO-9403387 (1994-02-01), None
patent: WO-9415723 (1994-07-01), None
patent: WO-9420480 (1994-09-01), None
patent: WO-9426731 (1994-11-01), None
patent: WO-9427980 (1994-12-01), None
patent: WO-9500501 (1995-01-01), None
patent: WO-9515316 (1995-06-01), None
patent: WO-9603387 (1996-02-01), None
patent: WO-9603388 (1996-02-01), None
patent: WO-9606840 (1996-03-01), None
patent: WO-9621667 (1996-07-01), None
patent: WO-9631509 (1996-10-01), None
patent: WO-9636623 (1996-11-01), None
patent: WO-9714691 (1997-04-01), None
patent: WO-9716435 (1997-05-01), None
patent: WO-9727749 (1997-08-01), None
patent: WO-9746521 (1997-12-01), None
patent: WO-9819672 (1998-05-01), None
patent: WO-9964417 (1999-12-01), None
patent: WO-0028988 (2000-05-01), None
patent: WO-0054756 (2000-09-01), None
patent: WO-0145703 (2001-06-01), None
patent: WO-0187343 (2001-11-01), None
patent: WO-03013432 (2003-02-01), None
patent: WO-03017996 (2003-03-01), None
Sorba, et al. “Mixed Antisecretory and gastroprotective activities of a new H2-Antagonist Containing a Nitric Oxide-donor Furoxan Moiety,” Arzneim. Forsch. Drug Res. 47: 849-854 (8 pages) (1997).
Brideau et al. “A human whole blood assay for clinical evaluation of biochemical efficacy of cyclooxygenase inhibitors,” Inflamm. Res. 45: 68-74 (7 pages) (1996).
Cerecetto, et al. “1,2,5-Oxadiazole N-oxide derivatives and related compounds as potential antitrypanosomal drugs: structure-activity relationships,” J. Med. Chem. 42: 1941-1950 (10 pages) (1999).
De Stilo, et al. “New 1,4-dihydropyridines conjugated to furoxanyl moieties, endowed with both nitric oxide-like and calcium channel antagonist vasodilator activities,” J. Med. Chem. 41: 5393-5401 (9 pages) (1998).
Fruttero, et al. “The furoxan system as a useful tool for balancing “hybrids” with mixed a1-antagonist and NO-like vasodilator activities,” J. Med. Chem. 38: 4944-4949 (6 pages) (1995).
Ignarro et al . “Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide,” Proc. Natl. Acad. Sci. 84: 9265-9269 (5 pages) (1987).
Cena et al. “Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin,” J. Med. Chem. 46: 747-754 (8 pages) (2003).
Oae et al. “Organic thionitrites and related substances,” Org. Prep. Proc. Int. 15(3): 165-198 (38 pages) (1983).
Palmer et al. “Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor,” Nature, 327: 524-526 (3 pages) (1987).
PCT/US07/06749 International Search Report mailed Sep. 12, 2007 (2 pages).
Rokach et al. “The isoprostanes: a perspective,” Prostaglandins, 54: 823-851 (29 pages) (1997).
Rokach et al. “Nomenclature of isoprostanes: a proposal,” Prostaglandins, 54: 853-873 (21 pages) (1997).
Wang et al. “Nitric oxide donors: chemical activities and biological applications,” Chem. Rev. 102: 1091-1134 (44 pages) (2002).
Anderson Rebecca
NiCox S.A.
Otton Alicia L
Wilmer Cutler Pickering Hale and Dorr LLP
LandOfFree
Nitric oxide enhancing prostaglandin compounds, compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Nitric oxide enhancing prostaglandin compounds, compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Nitric oxide enhancing prostaglandin compounds, compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4299170